See also this year's filing and all EDGAR filings for this company.
PDF Report 0001423824_2017_ALDER_BIOPHARMACEUTICALS_INC.pdf
Logs
| warning | Similarly named company. Duplicate? | None | {'details': [{'other_company': 'PROVECTUS BIOPHARMACEUTICALS INC.', 'shared_tokens': {'biopharmaceuticals'}}, {'other_company': 'REGENERX BIOPHARMACEUTICALS INC', 'shared_tokens': {'biopharmaceuticals'}}, {'other_company': 'KERYX BIOPHARMACEUTICALS INC', 'shared_tokens': {'biopharmaceuticals'}}]} |
| warning | Missing logo | subcommand.report | {} |
| info | Failed to set obs_EconomicCapitalRatio | industry.us_generic | {'reason': "KeyError('0001423824')"} |
| info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0001423824, ALDER BIOPHARMACEUTICALS INC
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 393,183,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 7,076,000 |
| 3 | remainder_Assets | 8,895,000 |
| 4 | LiabilitiesCurrent | 25,890,000 |
| 5 | LiabilitiesNoncurrent | 0 |
| 6 | remainder_Liabilities | 481,000 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 26,148,000 |
| 9 | ResearchAndDevelopmentExpense | 132,760,000 |
| 10 | remainder_Expenses | 113,000 |
| 11 | remainder_Revenues | 0 |
| 12 | remainder_NetIncome | 2,767,000 |
| 13 | remainder_ComprehensiveNetIncome | 453,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 409,154,000 |
| 1 | Liabilities | 26,371,000 |
| 2 | Expenses | 159,021,000 |
| 3 | Revenues | 0 |
| 4 | StockholdersEquity | 382,783,000 |
| 5 | NetIncome | -156,254,000 |
| 6 | ComprehensiveNetIncome | -156,027,500 |
| 7 | BaseVar | 298,883,000 |
| 8 | EconomicCapitalRatio | 2.31 |
Edgar->Model Mapping
Feature Distribution
